lifestyle.longislandreport.org

Author: SAB Biotherapeutics, Inc.

SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

March 19, 2026
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

March 17, 2026
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

March 17, 2026
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes

March 10, 2026
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights

March 9, 2026
SAB BIO to Participate in Upcoming Investor Conferences

March 2, 2026
SAB BIO to Participate in Upcoming Investor Conferences

February 10, 2026